Curanex Forms World Class Scientific Advisory Board

Core Insights - Curanex Pharmaceuticals Inc. has established a new Scientific Advisory Board to support its executive team and Board of Directors, focusing on the development of botanical drugs for inflammatory diseases [1][2] Group 1: Scientific Advisory Board - The Scientific Advisory Board will assist in research and development, including clinical trials and intellectual property enhancement, while also shaping the commercialization strategy [2] - The initial board will consist of five members, including two industry experts and three leading academic figures [3] Group 2: Company Overview - Curanex is a development-stage pharmaceutical company based in Jericho, New York, dedicated to botanical drugs for inflammatory diseases, with its lead candidate being Phyto-N [5] - Phyto-N is a botanical extract with proven anti-inflammatory properties, having a history of use in treating thousands of patients over 30 years in China [5] Group 3: Development Focus - The company has validated Phyto-N's effects in animal models for six inflammatory diseases, with a primary focus on moderate to severe ulcerative colitis [6] - Phyto-N is currently undergoing FDA-required preclinical studies, with Phase I clinical trials expected to start in Q4 2026, pending regulatory clearance [7]